Lung transplantation in children

Charles B. Huddleston, Jeffrey B. Bloch, Stuart C. Sweet, Maite De La Morena, G. Alexander Patterson, Eric N. Mendeloff

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: To report the authors' experience with pediatric lung transplantation (LTX) to provide an overview of patients selected for this procedure and their outcomes. Summary: Background Data Pediatric LTX differs from adults in many ways, including recipient size, indications, posttransplant care, and rehabilitation. Methods: Two hundred seven isolated lung transplants on 190 children under the age of 18 years were performed from 1990 to the present. This represents the single largest series of lung transplants in children in the world. Thirty-two patients were less than 1 year of age, 22 were 1 to 5 years of age, 32 were 5 to 10 years of age, and 121 were 10 to 18 years old. The groups by major diagnostic category were cystic fibrosis (n = 89), pulmonary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n = 12), pulmonary fibrosis (n = 15), and other (n = 26). The average age at the time of transplant was 9.5 ± 5.9 years (range 36 days to 18 years). Results: Survival by Kaplan-Meier analysis was 77% at 1 year, 62% at 3 years, and 55% at 5 years. There was no significant difference in survival according to primary diagnosis leading to LTX or age at LTX. There were 25 early (<60 days) and 61 late deaths. The most common cause of early deaths was graft failure (13/25, 52%). The most common causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61, 21%), and posttransplant malignancies (11/61, 18%). No patient died of acute rejection. In those surviving greater than 3 months (mean follow-up 3.5 years, range 3 months to 11 years), the overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overall incidence of posttransplant malignancies was 24/175 (14%). Major risk factors for the development of bronchiolitis obliterans were age older than 3 years, more than two episodes of acute rejection, and organ ischemic time longer than 180 minutes. Conclusions: In children, LTX is a high-risk but viable treatment for endstage pulmonary parenchymal and vascular disease. The major hurdle to overcome in long-term survival is bronchiolitis obliterans.

Original languageEnglish (US)
Pages (from-to)270-276
Number of pages7
JournalAnnals of Surgery
Volume236
Issue number3
DOIs
StatePublished - Sep 2002

Fingerprint

Bronchiolitis Obliterans
Lung Transplantation
Transplants
Vascular Diseases
Lung Diseases
Survival
Cause of Death
Pulmonary Alveolar Proteinosis
Pediatrics
Lung
Pulmonary Fibrosis
Kaplan-Meier Estimate
Cystic Fibrosis
Neoplasms
Rehabilitation
Incidence
Infection

ASJC Scopus subject areas

  • Surgery

Cite this

Huddleston, C. B., Bloch, J. B., Sweet, S. C., De La Morena, M., Patterson, G. A., & Mendeloff, E. N. (2002). Lung transplantation in children. Annals of Surgery, 236(3), 270-276. https://doi.org/10.1097/00000658-200209000-00003

Lung transplantation in children. / Huddleston, Charles B.; Bloch, Jeffrey B.; Sweet, Stuart C.; De La Morena, Maite; Patterson, G. Alexander; Mendeloff, Eric N.

In: Annals of Surgery, Vol. 236, No. 3, 09.2002, p. 270-276.

Research output: Contribution to journalArticle

Huddleston, CB, Bloch, JB, Sweet, SC, De La Morena, M, Patterson, GA & Mendeloff, EN 2002, 'Lung transplantation in children', Annals of Surgery, vol. 236, no. 3, pp. 270-276. https://doi.org/10.1097/00000658-200209000-00003
Huddleston CB, Bloch JB, Sweet SC, De La Morena M, Patterson GA, Mendeloff EN. Lung transplantation in children. Annals of Surgery. 2002 Sep;236(3):270-276. https://doi.org/10.1097/00000658-200209000-00003
Huddleston, Charles B. ; Bloch, Jeffrey B. ; Sweet, Stuart C. ; De La Morena, Maite ; Patterson, G. Alexander ; Mendeloff, Eric N. / Lung transplantation in children. In: Annals of Surgery. 2002 ; Vol. 236, No. 3. pp. 270-276.
@article{dbfe9520c99e4a8e8221f3333a322cd5,
title = "Lung transplantation in children",
abstract = "Objective: To report the authors' experience with pediatric lung transplantation (LTX) to provide an overview of patients selected for this procedure and their outcomes. Summary: Background Data Pediatric LTX differs from adults in many ways, including recipient size, indications, posttransplant care, and rehabilitation. Methods: Two hundred seven isolated lung transplants on 190 children under the age of 18 years were performed from 1990 to the present. This represents the single largest series of lung transplants in children in the world. Thirty-two patients were less than 1 year of age, 22 were 1 to 5 years of age, 32 were 5 to 10 years of age, and 121 were 10 to 18 years old. The groups by major diagnostic category were cystic fibrosis (n = 89), pulmonary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n = 12), pulmonary fibrosis (n = 15), and other (n = 26). The average age at the time of transplant was 9.5 ± 5.9 years (range 36 days to 18 years). Results: Survival by Kaplan-Meier analysis was 77{\%} at 1 year, 62{\%} at 3 years, and 55{\%} at 5 years. There was no significant difference in survival according to primary diagnosis leading to LTX or age at LTX. There were 25 early (<60 days) and 61 late deaths. The most common cause of early deaths was graft failure (13/25, 52{\%}). The most common causes of late death were bronchiolitis obliterans (35/61, 57{\%}), infection (13/61, 21{\%}), and posttransplant malignancies (11/61, 18{\%}). No patient died of acute rejection. In those surviving greater than 3 months (mean follow-up 3.5 years, range 3 months to 11 years), the overall rate of occurrence of bronchiolitis obliterans was 46{\%} (80/175) and the overall incidence of posttransplant malignancies was 24/175 (14{\%}). Major risk factors for the development of bronchiolitis obliterans were age older than 3 years, more than two episodes of acute rejection, and organ ischemic time longer than 180 minutes. Conclusions: In children, LTX is a high-risk but viable treatment for endstage pulmonary parenchymal and vascular disease. The major hurdle to overcome in long-term survival is bronchiolitis obliterans.",
author = "Huddleston, {Charles B.} and Bloch, {Jeffrey B.} and Sweet, {Stuart C.} and {De La Morena}, Maite and Patterson, {G. Alexander} and Mendeloff, {Eric N.}",
year = "2002",
month = "9",
doi = "10.1097/00000658-200209000-00003",
language = "English (US)",
volume = "236",
pages = "270--276",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Lung transplantation in children

AU - Huddleston, Charles B.

AU - Bloch, Jeffrey B.

AU - Sweet, Stuart C.

AU - De La Morena, Maite

AU - Patterson, G. Alexander

AU - Mendeloff, Eric N.

PY - 2002/9

Y1 - 2002/9

N2 - Objective: To report the authors' experience with pediatric lung transplantation (LTX) to provide an overview of patients selected for this procedure and their outcomes. Summary: Background Data Pediatric LTX differs from adults in many ways, including recipient size, indications, posttransplant care, and rehabilitation. Methods: Two hundred seven isolated lung transplants on 190 children under the age of 18 years were performed from 1990 to the present. This represents the single largest series of lung transplants in children in the world. Thirty-two patients were less than 1 year of age, 22 were 1 to 5 years of age, 32 were 5 to 10 years of age, and 121 were 10 to 18 years old. The groups by major diagnostic category were cystic fibrosis (n = 89), pulmonary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n = 12), pulmonary fibrosis (n = 15), and other (n = 26). The average age at the time of transplant was 9.5 ± 5.9 years (range 36 days to 18 years). Results: Survival by Kaplan-Meier analysis was 77% at 1 year, 62% at 3 years, and 55% at 5 years. There was no significant difference in survival according to primary diagnosis leading to LTX or age at LTX. There were 25 early (<60 days) and 61 late deaths. The most common cause of early deaths was graft failure (13/25, 52%). The most common causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61, 21%), and posttransplant malignancies (11/61, 18%). No patient died of acute rejection. In those surviving greater than 3 months (mean follow-up 3.5 years, range 3 months to 11 years), the overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overall incidence of posttransplant malignancies was 24/175 (14%). Major risk factors for the development of bronchiolitis obliterans were age older than 3 years, more than two episodes of acute rejection, and organ ischemic time longer than 180 minutes. Conclusions: In children, LTX is a high-risk but viable treatment for endstage pulmonary parenchymal and vascular disease. The major hurdle to overcome in long-term survival is bronchiolitis obliterans.

AB - Objective: To report the authors' experience with pediatric lung transplantation (LTX) to provide an overview of patients selected for this procedure and their outcomes. Summary: Background Data Pediatric LTX differs from adults in many ways, including recipient size, indications, posttransplant care, and rehabilitation. Methods: Two hundred seven isolated lung transplants on 190 children under the age of 18 years were performed from 1990 to the present. This represents the single largest series of lung transplants in children in the world. Thirty-two patients were less than 1 year of age, 22 were 1 to 5 years of age, 32 were 5 to 10 years of age, and 121 were 10 to 18 years old. The groups by major diagnostic category were cystic fibrosis (n = 89), pulmonary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n = 12), pulmonary fibrosis (n = 15), and other (n = 26). The average age at the time of transplant was 9.5 ± 5.9 years (range 36 days to 18 years). Results: Survival by Kaplan-Meier analysis was 77% at 1 year, 62% at 3 years, and 55% at 5 years. There was no significant difference in survival according to primary diagnosis leading to LTX or age at LTX. There were 25 early (<60 days) and 61 late deaths. The most common cause of early deaths was graft failure (13/25, 52%). The most common causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61, 21%), and posttransplant malignancies (11/61, 18%). No patient died of acute rejection. In those surviving greater than 3 months (mean follow-up 3.5 years, range 3 months to 11 years), the overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overall incidence of posttransplant malignancies was 24/175 (14%). Major risk factors for the development of bronchiolitis obliterans were age older than 3 years, more than two episodes of acute rejection, and organ ischemic time longer than 180 minutes. Conclusions: In children, LTX is a high-risk but viable treatment for endstage pulmonary parenchymal and vascular disease. The major hurdle to overcome in long-term survival is bronchiolitis obliterans.

UR - http://www.scopus.com/inward/record.url?scp=0036724801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036724801&partnerID=8YFLogxK

U2 - 10.1097/00000658-200209000-00003

DO - 10.1097/00000658-200209000-00003

M3 - Article

C2 - 12192313

AN - SCOPUS:0036724801

VL - 236

SP - 270

EP - 276

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -